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doi:10.1016/j.ejvs.2009.12.029Abstract Objective: Ectopic calcification and mediacalcinosis can be promoted by cortico-
steroid use. Aim of the present investigation is to describe macrovascular disease features
in patients with long-term corticosteroid therapy and symptomatic lower limb peripheral arte-
rial occlusive disease (PAD).
Methods: A consecutive series of 2783 patients undergoing clinical and angiographic work-up
of PAD were screened for long-term (>5 years) corticosteroid use (group A). Comparison was
performed to a randomly selected age-, sex- and risk factor-matched PAD control cohort from
the same series without corticosteroid use (group B). Patients with diabetes mellitus or severe
renal failure were excluded. Arterial calcification was evaluated by qualitative assessment on
radiographic images. Severity of atherosclerotic lesions was analysed from angiographic
images using a semi-quantitative score (Bollinger score).
Results: In general, 12 patients (5 males, mean age 78.5  9.0 years) with 15 ischaemic limbs
qualified to be enrolled in group A and were compared to 23 matching control patients
(6 2males, mean age 79.5  6 years) with 32 ischaemic limbs. Incompressibility of ankle
arteries determined by measurement of the ankle-brachial index was seen in 12 limbs (80%)
in group A compared to 3 limbs (9%) in group B (p Z 0.0009). No significant difference was
found comparing group A and B for segmental calcification, whereas comparison of the athero-
sclerotic burden using the angiographic severity score showed a significantly higher score at
the infragenicular arterial level in group A (p Z 0.001).
Conclusion: Findings suggest that the long-term corticosteroid therapy is associated with
a distally accentuated, calcifying peripheral atherosclerosis inducing arterial incompressibil-
ity. This occlusion pattern is comparable to patients with renal failure or diabetes. Further
research is required to support our observations.
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442 T. Willenberg et al.Ever since their introduction more than 50 years ago, corti-
costeroids have played a major role in the management of
a wide range of immunological, neoplastic and allergic
diseases. However, their use is limited by frequent adverse
events, which sometimes may outweigh their beneficial
effects. While side effects of corticosteroids such as osteo-
porosis, cataract and ocular hypertension were reported in
various studies,1e3 there are no clinical data on the macro-
vascular effects of long-term corticosteroid therapy. Results
of some animal and experimental studies suggest that
corticosteroids promote arterial calcification.4,5 The latter
is commonly accepted as mediacalcinosis and was found to
be associated with advanced age, diabetes mellitus, chronic
renal failure and osteoporosis.6e8 For many years, media-
calcinosis, also known as Mo¨nckeberg sclerosis, was consid-
ered a completely benign condition.9 Currently, it is thought
to lead to decreased arterial compliance with increased
pulse pressure, left ventricular hypertrophy, peripheral
vascular disease and altered coronary perfusion,7,10,11 and
has been associated with a substantially increased risk of
cardiovascular morbidity and mortality.12e14
Aim of the present study is to describe macrovascular
disease features in patients with peripheral arterial occlu-
sive disease (PAD) of the lower limb who have had long-
term corticosteroid therapy for the treatment of chronic
inflammatory disease. Our hypothesis is that the long-term
intake of corticosteroids increases arterial calcification and
is associated with a particular distal occlusive pattern as




A consecutive series of 2783 patients presenting to our
tertiary vascular referral centre for clinical and angio-
graphic work-up of symptomatic PAD between January 2004
and April 2008 were prospectively screened for long-term
corticosteroid use. Inclusion criteria for the present inves-
tigation were a documented, symptomatic PAD (Rutherford
clinical stage 2e6)16 and long-term corticosteroid therapy
defined as more than 5 years of intake (group A). Exclusion
criteria were diagnosis of diabetes mellitus defined as gly-
cosylated haemoglobin >6%, use of hypoglycemic drugs, or
renal insufficiency defined as calculated creatinine clear-
ance <30 ml min1.17
A PAD control cohortwithout corticosteroid therapy at the
time of presentation or within their documented medical
history was randomly selected from the same 2783 patients
presenting to our clinic between January 2004 and April 2008.
Control patients were matched in terms of age, sex and risk
factor e including smoking, hypertension and hypercholes-
terolemia e to case patients. The same exclusion criteria as
for the patient group were applied to the control group.
Clinical assessment
Routine assessments consisted of demographic data collec-
tion, history of cardiovascular risk factors, blood pressure
measurement, lipid status, serum glucose and creatinine.For the assessment of circulatory impairment in the affected
limb(s), systolic arterial pressures of the anterior and
posterior tibial arteries at the ankle were measured.
Measurements were taken by experienced nurses and
reported in clinical charts and a database. Of the two pres-
sure readings at the ankle, the higher one was chosen for
statistical analysis and for the calculation of the ankle-
brachial index (ABI). The ABI was calculated by dividing the
highest systolic arterial pressure reading at the ankle by the
systolic blood pressure in the arm.18 Tibial artery incom-
pressibility was assumedwhen the ABI was>1.15, which was
reported to be invariably associated with heavy contiguous
calcification in the total length of the tibial vessels.19 The
presence of critical limb ischaemiawas defined, according to
current consensus, as the presence of ischaemic rest pain for
more than 2 weeks or ischaemic tissue loss, associated with
an absolute ankle pressure <50 mmHg or first toe pressure
<30 mmHg.20
The presence of arterial hypertension was defined as
systolic blood pressure >140 mmHg and/or diastolic blood
pressure >80 mmHg, or if the patient was taking any anti-
hypertensive drugs. The presence of hyperlipidemia was
defined by total cholesterol levels >5 mmol le1 or high-
density lipoprotein (HDL) cholesterol <1 mmol le1 or low-
density lipoprotein (LDL) cholesterol > 2.6 mmol le1, or if
the patient was taking any lipid-lowering drug. Further-
more, patients were classified as smokers and non-smokers.
A positive smoking history (current or former smoker) was
defined by patients who had 1 pack-year or more of tobacco
use based on patient interview or chart documentation.
Qualitative assessment of vascular calcification
Vascular calcification was assessed using a scoring system
adapted from Adragao and co-workers,21 evaluating the
presence of linear calcifications on angiographic imaging in
each of the main arteries of the pelvis, thigh and calf. The
presence of linear calcifications was counted as 1 and their
absence as 0. The original score from Adragao was applied
for vascular calcifications in pelvic and hand X-rays.
Angiographic atherosclerosis severity score
Angiograms were read in a random order by two experi-
enced readers together (Diehm and Willenberg), blinded to
clinical data. Distribution and severity of the obstructive
lesions were analysed according to a semi-quantitative
angiographic score proposed by Bollinger.22 In brief, the
scoring system consisted of an additive score describing the
severity of the lesions visualised within each arterial
segment analysed (Table 1). The more severe the stenosis,
the higher is the score. A single lesion, multiple alterations
in half of the arterial segment or less and lesions in more
than half of the arterial segment lengths were given
different score numbers. With multiple lesions in one
arterial segment the highest severity score was considered
for analysis, that is, in the presence of an occlusion, pla-
ques or stenoses were not scored; when both categories of
stenoses (>50% and <50%) were present, plaques were not
scored; for each type of occlusion only one length category
was indicated.
Table 1 Description of occlusive patterns according to the Bollinger scoring system.23
Occlusion Stenosis >50% Stenosis <50% Plaque <25% Location
4 2 1 Single
13 5 3 2 Multiple < half of vessel
15 6 4 3 Multiple > half of vessel
The vertical columns represent the different atherosclerotic lesions defined, the horizontal ones the extent of the lesions detected in
each of the artery segments. The numbers appearing in the single fields correspond to the score numbers. The additive score is obtained
by adding the scores for the four different lesions.
2783 patients requiring angiographic imaging for symptomatic PAD 
screened for steroid therapy for ≥ 5years
38 patients identified
23 patients excluded due to 
- diabetes mellitus; n=12
- renal failure (GFR < 30ml/min); n=3
- diabetes plus renal failure; n=8
- no matching control; n=3
12 patients age, sex and risk factor matched 
to 23 control patients  
Figure 1 Decision flow chart of screening process.
Impact of Long-term Corticosteroid Therapy 443The following arteries were evaluated for the qualitative
assessment of vascular calcification and angiographic
grading: common iliac artery (CIA), external iliac artery
(EIA), common femoral artery (CFA), superficial femoral
artery (SFA), deep femoral artery (DFA), popliteal artery
(PPA), anterior tibial artery (ATA), tibioperoneal trunk
(TPT), posterior tibial artery (PTA) and peroneal artery
(PA).
The location of target lesions was grouped as iliaco-
femoral (common, external iliac artery and CFA), femoro-
popliteal (SFA, DFA and PPA) and infrageniculate or distal
(tibiofibular trunk, ATA, PTA and PA). For statistical analysis
average scores of these three segments including the latter
mentioned arterial vessels were determined.
Statistical analysis
Demographic and clinical characteristics of the study pop-
ulation are reported as mean  SD for continuous variables,
and as numbers and percentages for categorical variables.
Comparisons were performed using the KruskalleWallis test
and the Student t-test for continuous variables, and the
Fisher exact test for discrete variables. A p-value <0.05
was considered statistically significant. All calculations
were performed using SPSS (version 13.0, SPSS, Chicago, IL,
USA) and Stata (version 10.1, Stata Corporation, College
Station, TX, USA).
Ethics
The study was carried out based on the Declaration of
Helsinki23 and all patients gave informed consent prior to
inclusion in the study.
Results
Out of the 2783 consecutive patients with clinical and
angiographic work-up for symptomatic PAD, we identified
38 patients with long-term corticosteroid therapy for at
least 5 years. Twenty-three of these 38 patients were
excluded due to the presence of diabetes mellitus and renal
insufficiency (Fig. 1). Fifteen patients being on long-term
steroid therapy fulfilling the inclusion criteria were identi-
fied. Age-, sex- and risk factor-matched controls without
diabetes mellitus and without severe renal insufficiency
and with no use of corticosteroids in their medical history
were found for 12 of these 15 patients, so that these 12
patients (5 males, mean age 78.5  9.0 years) with 15
ischaemic legs (group A) entered into the analysis. Indica-
tions for long-term corticosteroid therapy in these 12patients were rheumatoid polyarthritis (n Z 3), poly-
myalgia rheumatica (n Z 3), scleroderma (n Z 1), Crohn’s
disease (n Z 1), lupus erythematosis (n Z 2), Wegener’s
disease (n Z 1) and giant cell arteritis (n Z 1). The sex-,
age- and risk factor-matched PAD control cohort from the
same consecutive series of PAD patients consisted of 23
patients (six males, mean age 79.5  6 years) with 32
ischaemic limbs.
Clinical stage of PAD
Case patients showed a statistically significant worst clin-
ical stage at presentation. Eight of 15 legs (53%) of group A
were diagnosed with a Rutherford stage 4e6 consistent
with the definition of critical limb ischaemia. In the control
cohort, 3 of 32 legs (9%) were diagnosed with a Rutherford
stage 4e6 and 29 of 32 (91%) legs with a Rutherford stage
2e3 (p Z 0.002).
Ankle-brachial pressure measurements
Measurement of ankle and brachial pressures revealed
arterial incompressibility of lower limb arteries consistent
with mediacalcinosis in 12 of 15 (80%) of the affected limbs
in group A and in 3 of 32 limbs (9%) in group B, respectively
(p < 0.0001).
Qualitative assessment of vascular calcification
Substantial arterial calcification of all three vascular
segments was more pronounced in patients receiving long-
Table 3 Average of Bollinger score of the three segments
which were evaluated by two independent observers. The
average was obtained by adding the score of the single
arterial segment divided by the number of single arterial
segment of each segment. Group A, glucocorticoid case PAD
patients, n Z 12 (15 limbs); group B, case control PAD
patients, n Z 23 (32 limbs). Iliaco-femoral defines as
common femoral artery, common iliac artery, external iliac
artery; femoro-politeal defined as superficial femoral
artery, deep femoral artery, popliteal artery; infragenicular
defined as anterior tibial artery, tibioperoneal trunk,
posterior tibial artery, peroneal artery.
Arterial segment Average of angiographic






Iliaco-femoral 1.33 (0.5) 1.56 (2.2) 0.12
Femoro-popliteal 3.15 (2.3) 3.79 (3.3) 0.61
Infragenicular 7.85 (2.9) 3.46 (2.8) 0.0001
a KruskaleWallis rank based comparison.
444 T. Willenberg et al.term steroid therapy, but was also found in the control
cohort (Table 2). Of note, 12/12 legs (100%) in the steroid
group and 1/12 legs (7%) of control patients exhibiting
ankle arterial incompressibility showed linear calcification
of infragenicular arteries (p < 0.001).
Angiographic severity score
No significant differences were observed in the athero-
sclerotic burden of iliaco-femoral arteries and femoro-
popliteal arteries between both groups (Table 3). By
contrast, infragenicular arteries showed a significantly
higher atherosclerotic burden in patients from group A as
compared with patients from group B (p < 0.0001) (Table 3,
Fig. 2).
Discussion
The present consecutive series describes macrovascular
disease features of PAD patients on long-term glucocorti-
costeroid therapy for various chronic inflammatory
diseases. Findings suggest that long-term corticosteroid
therapy is associated with a distally accentuated, calcifying
peripheral atherosclerosis inducing arterial incompressi-
bility. An occlusion pattern very comparable to patients
with renal failure or diabetes was excluded in this series.
The majority of patients with long-term corticosteroid
therapy showed mediacalcinosis with incompressibility of
ankle arteries, and in all of these patients linear calcifica-
tion of infragenicular arteries on plain X-ray was observed.
Mediacalcinosis is frequently observed in patients with
renal insufficiency or diabetes mellitus predefined to be
excluded in the present series.15 Mediacalcinosis with
incompressibility of ankle arteries was significantly less in
legs of the control group although linear calcification at the
infragenicular arteries on plain X-ray was observed in 37% ofTable 2 Vascular calcification as assessed using a scoring
system adapted from Adragao and co-workers22 evaluating
the presence of linear calcifications on angiographic
imaging in each of the main arteries of the pelvis, thigh and
calf. Presence of linear calcifications were counted as 1 and
its absence as 0. Group A, glucocorticoid case PAD patients,
n Z 12 (15 limbs); group B, case control PAD patients,
n Z 23 (32 limbs). Iliaco-femoral defines as common
femoral artery, common iliac artery, external iliac artery;
femoro-politeal defined as superficial femoral artery, deep
femoral artery, popliteal artery; infragenicular defined as






(n Z 15 legs)
N(%)
Group B
(n Z 32 legs)
N(%)
Iliaco-femoral 8 (53) 12 (37) 0.35
Femoro-popliteal 10 (67) 14 (43) 0.21
Infragenicular 9 (60) 12 (37) 0.21
a Fisher’s exact test.these legs. This might be simply explained by the qualita-
tive character of our analysis adapted to the scoring of
Adragao21 which does not give any quantitative informa-
tion. However, qualitative assessment of calcification in
group A by means of plain X-ray revealed widespread
arterial wall calcification in the peripheral flow path of
pelvis and leg with the highest prevalence in the lower limbFigure 2 Angiography of a patient on long-term corticoste-
roid therapy. The anterior tibial artery shows severe calcifi-
cation and obstruction (arrow). The proximal part of the vessel
shows two stents after angioplasty.
Impact of Long-term Corticosteroid Therapy 445distally. These findings were consistent with the clinical
presentation and results of ABI measurement. By contrast,
the matched control cohort of PAD patients did not show
this pattern and mediacalcinosis was only observed in 3/32
legs while arterial wall calcifications were less frequent.
Comparison of the iliaco-femoral, femoro-popliteal and
infragenicular arterial segments between both groups
revealed a significant augmentation of atherosclerotic
burden in infragenicular arteries in patients of group A. This
centrifugal pattern of atherosclerosis is also typical for
patients with diabetes mellitus or end-stage renal disease.15
Of note, we did not observe any augmented atherosclerotic
involvement of the DFA in patients on long-term steroid
therapy as often seen in patients with diabetes mellitus.15
Consistent with the more distal disease burden in steroid
case patients, clinical stage was clearly more advanced as
compared with the case control cohort with case and control
PAD patients selected from the same consecutive patient
series using identical inclusion and exclusion criteria.
Mechanisms of vascular calcification promoted by corti-
costeroids are not entirely understood yet. Recently, it has
been shown that corticosteroids mediate osteoblastic
differentiation.8 The cells e which may be derived from
stem cells or differentiation of existing cells like pericytes
or smooth muscle cells e have been identified to promote
calcification of the extracelluar matrix in the absence of
a cartilage template.4 It has also been shown that dexa-
methasone enhances the differentiation of pericytes which
reside in the vascular wall, exhibiting decreased expression
of osteopontin and matrix G1a protein as well as vascular
calcification associated factor mRNA, which results in
increased alkaline phosphatase activity and calcium
deposition.4
Hypotheses explaining site selectivity of atherosclerotic
lesions include hemodynamic stress related to arterial
geometry, and cellular anatomic or biochemical variations
in the arterial wall.24 Iliac arteries are characterised by
elastic fibres, whereas femoral and infragenicular arteries
contain progressively more muscular elements. Moreover,
the relation of arterial lumen to wall thickness decreases
from proximal to distal, generating both, an alteration in
arterial flow and shear stress associated with endothelial
dysfunction, and an early type of atherosclerotic lesions at
sites with low shear rate and disturbed flow.15
Several authors reported on the cardiovascular risk of
patients requiring corticosteroid therapy.25e27 Results are
heterogeneous, and the overall effect of corticosteroid on
the cardiovascular system and risk of cardiovascular events
remains unclear. Wei and co-workers26 reported a three-fold
increased risk for cardiovascular events in high-dose corti-
costeroid users (>7.5mg day1). Davis et al.28 found a three-
fold elevated risk for cardiovascular events in rheumatoid
factor-positive patients with rheumatoid arthritis, whereas
Kremers and colleagues25 did not find an association
between corticosteroids and elevation of risk for cardio-
vascular events in patients with polymyalgia rheumatica.
Corticosteroids may indirectly increase the risk of cardio-
vascular disease through their adverse effects on traditional
cardiovascular risk factors.29 This may be one of the
components increasing the risk of cardiovascular disease,
which was found to be independent of traditional cardio-
vascular risk factors in patients with rheumatoid arthritis.30Due to the complexmechanisms of vascular calcification and
plaque formation, clinical data including mainly heteroge-
neous settings of cardiovascular risk factors will always be
limited in their significance. A mechanism that may be
independently associated with cardiovascular risk and
macrovascular disease features is the inflammatory activity
related to the disease entity treated with corticosteroids,
and this might influence atherosclerotic progression.31
This study has several limitations. First, the limited
number of patients hampers our ability to draw definitive
conclusions. This is, however, contra-balanced by meeting
strict inclusion and exclusion criteria of the patient pop-
ulation analysed in the present series. Second, as the present
study is descriptive it cannot be excluded that the inflam-
matory activity of the disease entity being treated with
corticosteroids influenced atherosclerotic progression,31e33
whereby the extraordinary trend for calcification is consis-
tent with mechanisms related to corticosteroids.4,5 Even if
the mechanism remains unclear, our findings should be rec-
ognised by various specialists treating patients particularly
underlining the risk of severe distally accentuated arterial
disease. Third, the advanced age of the study populationmay
have contributed to the presence of vascular calcification
and mediacalcinosis.8 However, the latter is hardly possible
considering the data of the age-, sex- and risk factor-
matched control group, which shows significantly less
mediacalcinosis.
Conclusion
Results of this consecutive series suggest that long-term
corticosteroid therapy for the treatment of chronic
inflammatory disease might be associated with a distally
dominated calcifying peripheral atherosclerosis. The
distribution pattern of lower limb atherosclerosis is
comparable to that of patients with severe renal failure or
long-standing diabetes, suggesting that similar pathogenic
mechanisms may play a role. Further investigations are
necessary to confirm our findings, explain the effects and
define consequences of corticosteroid use on peripheral
vascular vessels.
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